Biocryst Pharmaceuticals (BCRX) Inventory (2010 - 2026)

Biocryst Pharmaceuticals has reported Inventory for 15 years, with the latest figure at $6.0 million in Q1 2026.

• For the quarter ending Q1 2026, Inventory fell 12.92% year-over-year to $6.0 million; the trailing twelve-month figure through Mar 2026 stood at $6.0 million (down 12.92% YoY), and the FY2025 full-year result was $5.4 million, down 33.25% from the prior year.
• Inventory for Q1 2026 stood at $6.0 million, up from $5.4 million in the prior quarter.
• The five-year high for Inventory was $29.8 million in Q1 2024, with the low at $4.4 million in Q2 2024.
• Historically, Inventory has averaged $16.8 million across 5 years, with a median of $16.1 million in 2022.
• Annual changes were most pronounced in 2022 — Inventory soared 215.74% — and 2024, when it tumbled 83.54%.
• Biocryst Pharmaceuticals' Inventory stood at $27.5 million in 2022, then climbed by 4.18% to $28.7 million in 2023, then tumbled by 71.81% to $8.1 million in 2024, then slumped by 33.25% to $5.4 million in 2025, then gained by 10.87% to $6.0 million in 2026.
• The last three Inventory figures came in at $6.0 million (Q1 2026), $5.4 million (Q4 2025), and $5.2 million (Q3 2025), per Business Quant data.